#87FUZKK atlas leaders 1–100

Telix Pharmaceuticals

Australia · Australia and New Zealand

Peptides and complex injectablesOncology / ADC / high-potencyRadiopharmaceuticals

Manufacturing profile

Peptides and complex injectables
Oncology / ADC / high-potency
Radiopharmaceuticals

Country: Australia

Macro-region: Australia and New Zealand

Selection basis

The company is placed in positions 1–100 as a major manufacturer, biopharmaceutical group, generics/API/CDMO leader or a significant regional manufacturing participant.

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. China, India, Israel, the USA and the European scope are excluded because separate atlases already cover them.

Representative manufacturing and QC chain

  1. 1Peptide synthesis or recombinant upstream
  2. 2Chromatography and UF/DF
  3. 3HPLC/LC-MS and CE peptide mapping
  4. 4Sterile filtration and cartridge/vial filling
  5. 5Particles, sterility, endotoxin and cold-chain release
  6. 6Contained dispensing and high-potency handling
  7. 7Chemical synthesis or biologic upstream
  8. 8Purification and formulation
  9. 9HPLC/LC-MS/CE and potency analytics

Relevant FUZKK packages

Suggested first pilot

  1. Confirm one real product, method or recurring QC review.
  2. Record the instrument, export format and current specification.
  3. Select 3–7 utilities from the map above.
  4. Run a PASS/FAIL sample and agree the expected output.
  5. After user validation, expand to other products and sites.

Mapping boundary

The Top 300 is a FUZKK atlas priority rather than a single official revenue table. China, India, Israel, the USA and the European scope are excluded because separate atlases already cover them.

Methodology